Bibliographies thématiques / Idiopathic pulmonary fibrosi / Articles de revues

Articles de revues sur le sujet « Idiopathic pulmonary fibrosi »

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Idiopathic pulmonary fibrosi.
Auteur : Grafiati
Publié le 14 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Idiopathic pulmonary fibrosi ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Lettieri, Christopher J., Ganesh R. Veerappan, Donald L. Helman, Charles R. Mulligan et Andrew F. Shorr. « Safety of Surgical Lung Biopsy in Suspected Idiopathic Pulmonary Fibrosi ». Chest 124, no 4 (janvier 2003) : 116S. http://dx.doi.org/10.1378/chest.124.4_meetingabstracts.116s.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Plataki, Maria, Anastassios Koutsopoulos, John Drossitis, George Delides, Nikolaos M. Siafakas et Demosthenes Bouros. « Expression of Apoptosis-Regulatory Genes in Epithelial Cells in Patients With Idiopathic Pulmonary Fibrosi ». Chest 124, no 4 (janvier 2003) : 192S. http://dx.doi.org/10.1378/chest.124.4_meetingabstracts.192s-b.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Bell, Amanda M., Steven D. Nathan, Andrew F. Shorr, Scott D. Barnett et Donald L. Helman. « The Effect of Interferon Alone vs Interferon Plus Corticosteroids in Patients With Idiopathic Pulmonary Fibrosi ». Chest 124, no 4 (janvier 2003) : 117S. http://dx.doi.org/10.1378/chest.124.4_meetingabstracts.117s-a.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

NS, Mahesh, Sadanand C. D et Durga Lawande. « Clinical Profile of Idiopathic Pulmonary Fibrosis ». Academia Journal of Medicine 2, no 2 (24 juillet 2019) : 86–89. http://dx.doi.org/10.21276/ajm.2019.2.2.22.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

N, Mahesh, Sadanand C. D et Durga Lawande. « Management of Idiopathic Pulmonary Fibrosis Cases at a Tertiary Care Hospital ». Academia Journal of Medicine 2, no 2 (24 juillet 2019) : 90–95. http://dx.doi.org/10.21276/ajm.2019.2.2.23.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Nakanishi, Yu, Yasushi Horimasu, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto et al. « IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis ». PLOS ONE 16, no 6 (4 juin 2021) : e0252594. http://dx.doi.org/10.1371/journal.pone.0252594.

Texte intégral
Résumé :
Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow. To identify novel biomarkers that can support the diagnosis and/or prognostic prediction of idiopathic pulmonary fibrosis, we performed gene expression analysis, and the mRNA of interleukin-18 binding protein was increasingly expressed in patients with idiopathic pulmonary fibrosis compared with healthy controls. Therefore, we hypothesized that the interleukin-18 binding protein can serve as a diagnostic and/or prognostic biomarker for idiopathic pulmonary fibrosis. We investigated the expression of interleukin-18 binding protein in lung tissue, bronchoalveolar lavage fluid, and serum. Additionally, the correlation between interleukin-18 binding protein expression levels and the extent of fibrosis was investigated using mouse models of lung fibrosis induced by subcutaneous bleomycin injections. Serum interleukin-18 binding protein levels were significantly higher in idiopathic pulmonary fibrosis patients (5.06 ng/mL, interquartile range [IQR]: 4.20–6.35) than in healthy volunteers (3.31 ng/mL, IQR: 2.84–3.99) (p < 0.001). Multivariate logistic regression models revealed that the correlation between serum interleukin-18 binding protein levels and idiopathic pulmonary fibrosis was statistically independent after adjustment for age, sex, and smoking status. Multivariate Cox proportional hazard models revealed that serum interleukin-18 binding protein levels were predictive of idiopathic pulmonary fibrosis disease prognosis independent of other covariate factors (hazard ratio: 1.655, 95% confidence interval: 1.224–2.237, p = 0.001). We also demonstrated a significant positive correlation between lung hydroxyproline expression levels and interleukin-18 binding protein levels in bronchoalveolar lavage fluid from bleomycin-treated mice (Spearman r = 0.509, p = 0.004). These results indicate the utility of interleukin-18 binding protein as a novel prognostic biomarker for idiopathic pulmonary fibrosis.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Gavrysyuk, V. K., Y. O. Dziublyk, E. O. Merenkova, O. V. Strafun et O. V. Bychenko. « PROGRESSIVE PULMONARY FIBROSIS IN LIGHT OF THE ATS/ERS/JRS/ALAT 2022 CLINICAL GUIDELINES ». Ukrainian Pulmonology Journal 30, no 4 (2022) : 51–57. http://dx.doi.org/10.31215/2306-4927-2022-30-4-51-57.

Texte intégral
Résumé :
Idiopathic pulmonary fibrosis – is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in 50 years and older patients, limited to the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). In 2000 American thoracic society (ATS) and European respiratory society (ERS) published the first international; statement on diagnosis and treatment of IPF American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. In 2011 there was published a new statement on diagnosis and treatment of IPF, approved by Japan respiratory society (JTS) and Latin American thoracis society (ALTS) – An Official ATS/ERS/JRS/AL : Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. In 2015 section “Treatment” and in 2018 section “Diagnosis” were revised. It is known that in part of patients with such interstitial lung diseases (ILD) as idiopathic interstitial pneumonia, systemic sclerosis, pneumoconiosis, chronic hypersensitivity pneumonitis, sarcoidosis the disease may acquire a progressive uncontrolled development with the combination of symptoms called progressive pulmonary fibrosis (PPF). At the same time the results of successful use of antifibrotic therapy have been published recently (SENSCIS, INBUILD studies). All this provided the rationale for extended indications for use of antifibrotic therapy to cover other ILDs with the features of PPF. In this connection, ATS, ERS, JRS and ALAT experts published in May 2022 An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults, in which along with the partial changes regarding the principles of diagnosis and treatment of IPF, the definition, diagnosis criteria and management of PPF due to other fibrosing ILDs were presented. The article presents the major statements of new guideline regarding the terminology, diagnosis and treatment of PPF. Key words: progressive pulmonary fibrosis, definition, diagnosis criteria, treatment.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Rawahi, Yasmeen. « Pirfenidone Experience in Idiopathic Pulmonary Fibrosis at a Tertiary Hospital in Oman ». Journal of Thoracic Disease and Cardiothoracic Surgery 1, no 1 (12 juin 2020) : 01–06. http://dx.doi.org/10.31579/2693-2156/001.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Baddini-Martinez, José, Bruno Guedes Baldi, Cláudia Henrique da Costa, Sérgio Jezler, Mariana Silva Lima et Rogério Rufino. « Update on diagnosis and treatment of idiopathic pulmonary fibrosis ». Jornal Brasileiro de Pneumologia 41, no 5 (octobre 2015) : 454–66. http://dx.doi.org/10.1590/s1806-37132015000000152.

Texte intégral
Résumé :
Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of unknown etiology, which is associated with a progressive decrease in pulmonary function and with high mortality rates. Interest in and knowledge of this disorder have grown substantially in recent years. In this review article, we broadly discuss distinct aspects related to the diagnosis and treatment of idiopathic pulmonary fibrosis. We list the current diagnostic criteria and describe the therapeutic approaches currently available, symptomatic treatments, the action of new drugs that are effective in slowing the decline in pulmonary function, and indications for lung transplantation.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Averyanov, A. V., et V. N. Lesnyak. « FROM IDIOPATHIC FIBROSING ALVEOLITIS TO IDIOPATIC LUNGS FIBROSIS ». Journal of Clinical Practice 7, no 4 (15 décembre 2016) : 58–65. http://dx.doi.org/10.17816/clinpract7458-65.

Texte intégral
Résumé :
The second part of the analytical review devoted to features of the clinical course and diagnosis of idiopathic pulmonary fibrosis. Special attention is paid to the specific CT symptoms allows diagnosis without lung biopsy. Current approaches to invasive diagnostics and perspectives of cryoprobe are discussed.
Styles APA, Harvard, Vancouver, ISO, etc.
11

Averyanov, A. V. « FROM IDIOPATHIC FIBROSING ALVEOLITIS TO IDIOPATIC LUNGS FIBROSIS ». Journal of Clinical Practice 7, no 3 (15 septembre 2016) : 73–76. http://dx.doi.org/10.17816/clinpract7373-76.

Texte intégral
Résumé :
In this paper we try to present the current state of knowledge of the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), and to express our view on the problems and their solution, without which it is very difficult to improve the quality of medical care for IPF-patients in Russia.
Styles APA, Harvard, Vancouver, ISO, etc.
12

Ricci, Francesca, Luca Pugliese, Armando Ugo Cavallo, Marco Forcina, Vincenzo De Stasio, Matteo Presicce, Federica Di Tosto et al. « Highlights of high-resolution computed tomography imaging in evaluation of complications and co-morbidities in idiopathic pulmonary fibrosis ». Acta Radiologica 61, no 2 (25 juin 2019) : 204–18. http://dx.doi.org/10.1177/0284185119857435.

Texte intégral
Résumé :
Idiopathic pulmonary fibrosis (IPF) represents a condition included in the heterogeneous group of interstitial lung diseases without known causes. The recent ATS/ERS/JRS/ALAT guidelines and the white paper published by the Fleischner Society have well-defined diagnosis and management of idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis management is complex because it is also influenced by several co-morbidities and complications. The new frontier in idiopathic pulmonary fibrosis is represented by the effort to understand the complex mechanism of the pathogenesis and progression of disease in order to predict several consequences and co-morbidities. In our review, we tried to distinguish co-morbidities from complications of idiopathic pulmonary fibrosis. In each complication, we have reviewed the existing literature and we have emphasized the complex pathobiological pathway which links the progression of idiopathic pulmonary fibrosis to the development of the complication itself. For every co-morbidity, we tried to identify share common risk factors which explain the coexistence of idiopathic pulmonary fibrosis with its co-morbidities. We then analyzed high-resolution computed tomography (CT) aspects of co-morbidities and complications of idiopathic pulmonary fibrosis that the radiologist should be aware of. In this review, we focused on the role of high-resolution CT imaging in the evaluation of co-morbidities and complications in idiopathic pulmonary fibrosis because their early diagnosis and treatment could change the prognosis in patients with idiopathic pulmonary fibrosis. We have also pointed out that in some cases the final combined quantitative CT tools and conventional visual CT score would allow to get an accurate analysis and quantification of disease progression, co-morbidities, and complications of idiopathic pulmonary fibrosis in order to improve staging systems in idiopathic pulmonary fibrosis.
Styles APA, Harvard, Vancouver, ISO, etc.
13

Bargagli, Elena, Rosa Metella Refini, Miriana d’Alessandro, Laura Bergantini, Paolo Cameli, Lorenza Vantaggiato, Luca Bini et Claudia Landi. « Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis ». International Journal of Molecular Sciences 21, no 16 (7 août 2020) : 5663. http://dx.doi.org/10.3390/ijms21165663.

Texte intégral
Résumé :
Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder limited to the lung. New findings, starting from our proteomics studies on IPF, suggest that systemic involvement with altered molecular mechanisms and metabolic disorder is an underlying cause of fibrosis. The role of metabolic dysregulation in the pathogenesis of IPF has not been extensively studied, despite a recent surge of interest. In particular, our studies on bronchoalveolar lavage fluid have shown that the renin–angiotensin–aldosterone system (RAAS), the hypoxia/oxidative stress response, and changes in iron and lipid metabolism are involved in onset of IPF. These processes appear to interact in an intricate manner and to be related to different fibrosing pathologies not directly linked to the lung environment. The disordered metabolism of carbohydrates, lipids, proteins and hormones has been documented in lung, liver, and kidney fibrosis. Correcting these metabolic alterations may offer a new strategy for treating fibrosis. This paper focuses on the role of metabolic dysregulation in the pathogenesis of IPF and is a continuation of our previous studies, investigating metabolic dysregulation as a new target for fibrosis therapy.
Styles APA, Harvard, Vancouver, ISO, etc.
14

Cottin, Vincent, Nikhil A. Hirani, David L. Hotchkin, Anoop M. Nambiar, Takashi Ogura, María Otaola, Dirk Skowasch et al. « Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases ». European Respiratory Review 27, no 150 (21 décembre 2018) : 180076. http://dx.doi.org/10.1183/16000617.0076-2018.

Texte intégral
Résumé :
Although these conditions are rare, a proportion of patients with interstitial lung diseases (ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated with worsening respiratory symptoms, lung function decline, limited response to immunomodulatory therapies, decreased quality of life and, potentially, early death. Idiopathic pulmonary fibrosis may be regarded as a model for other progressive-fibrosing ILDs. Here we focus on other ILDs that may present a progressive-fibrosing phenotype, namely idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, connective tissue disease-associated ILDs (e.g.rheumatoid arthritis-related ILD), fibrotic chronic hypersensitivity pneumonitis, fibrotic chronic sarcoidosis and ILDs related to other occupational exposures. Differential diagnosis of these ILDs can be challenging, and requires detailed consideration of clinical, radiological and histopathological features. Accurate and early diagnosis is crucial to ensure that patients are treated optimally.
Styles APA, Harvard, Vancouver, ISO, etc.
15

Jeldres, Alejandro, et Gonzalo Labarca. « Is nintedanib effective for idiopathic pulmonary fibrosis ? » Medwave 17, Suppl2 (18 mars 2017) : e6918-e6918. http://dx.doi.org/10.5867/medwave.2017.6918.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
16

Shumar, John N., Abhimanyu Chandel et Christopher S. King. « Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD) : Building on INBUILD ». Journal of Clinical Medicine 10, no 11 (25 mai 2021) : 2285. http://dx.doi.org/10.3390/jcm10112285.

Texte intégral
Résumé :
Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical similarities to idiopathic pulmonary fibrosis. Two antifibrotic medications, nintedanib and pirfenidone, have been approved for use in patients with idiopathic pulmonary fibrosis. Recently completed randomized controlled trials have demonstrated the clinical efficacy of antifibrotic therapy in patients with PF-ILD. The validation of efficacy of antifibrotic therapy in PF-ILD has changed the treatment landscape for all of the fibrotic lung diseases, providing a new treatment pathway and opening the door for combined antifibrotic and immunosuppressant drug therapy to address both the fibrotic and inflammatory components of ILD characterized by mixed pathophysiologic pathways.
Styles APA, Harvard, Vancouver, ISO, etc.
17

Swigris, Jeffrey, Katelyn Cutts, Natalia Male, Michael Baldwin, Klaus B. Rohr et Donald M. Bushnell. « The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease ». ERJ Open Research 7, no 2 (11 mars 2021) : 00145–2020. http://dx.doi.org/10.1183/23120541.00145-2020.

Texte intégral
Résumé :
The Living with Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire was developed with substantial input from patients with idiopathic pulmonary fibrosis (IPF) to assess symptoms and health-related quality of life (HRQoL). Because IPF is the prototypical chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype, we expanded applicability of the L-IPF by deleting the word “idiopathic”, creating the L-PF (Living with Pulmonary Fibrosis) questionnaire, and then assessed its relevance among patients with progressive fibrosing ILDs in one-to-one interviews.Patients in the USA and Germany with any progressive fibrosing ILD other than IPF were asked about their disease and symptoms, completed the 44-item L-PF questionnaire (comprising two modules that assess symptoms and impacts of disease) and then answered a series of debriefing questions. Interviews were recorded, transcribed and coded for qualitative content analysis.20 patients were interviewed, but time constraints meant not all were asked about all items. The most frequent diagnoses were rheumatoid arthritis-associated ILD (25%) and mixed connective tissue disease-associated ILD (20%). Almost all patients endorsed the symptoms assessed by the L-PF: shortness of breath (19 out of 20 patients), cough (19 out of 20) and fatigue (18 out of 20). Most patients endorsed impacts of progressive fibrosing ILD on activities of daily living, physical well-being, sleep, emotional well-being, and social aspects of their lives. Most patients had an overall positive impression of the Symptoms module and understood items as intended. All seven patients asked understood the items of the Impacts module.The L-PF contains concepts relevant and important to patients with progressive fibrosing ILD, and items are understood as intended.
Styles APA, Harvard, Vancouver, ISO, etc.
18

Morrow, Lee E., Daniel Hilleman et Mark A. Malesker. « Management of patients with fibrosing interstitial lung diseases ». American Journal of Health-System Pharmacy 79, no 3 (5 octobre 2021) : 129–39. http://dx.doi.org/10.1093/ajhp/zxab375.

Texte intégral
Résumé :
Abstract Purpose This article summarizes the appropriate use and pharmacology of treatments for fibrosing interstitial lung diseases, with a specific focus on the antifibrotic agents nintedanib and pirfenidone. Summary The interstitial lung diseases are a heterogenous group of parenchymal lung disorders with a common feature—infiltration of the interstitial space with derangement of the normal capillary-alveolar anatomy. Diseases characterized by fibrosis of the interstitial space are referred to as the fibrosing interstitial lung diseases and often show progression over time: idiopathic pulmonary fibrosis is the most common fibrotic interstitial lung disease. Historically, therapies for fibrosing lung diseases have been limited in number, questionable in efficacy, and associated with potential harms. Food and Drug Administration (FDA) approval of the antifibrotic agents nintedanib and pirfenidone for idiopathic pulmonary fibrosis in 2014 heralded an era of reorganization of therapy for the fibrotic interstitial lung diseases. Subsequent investigations have led to FDA approval of nintedanib for systemic sclerosis–associated interstitial lung disease and interstitial lung diseases with a progressive phenotype. Although supportive care and pulmonary rehabilitation should be provided to all patients, the role(s) of immunomodulators and/or immune suppressing agents vary by the underlying disease state. Several agents previously used to treat fibrotic lung diseases (N-acetylcysteine, anticoagulation, and pulmonary vasodilators) lack efficacy or cause harm. Conclusion With the introduction of effective pharmacotherapy for fibrosing interstitial lung disease, pharmacists have an increasingly important role in the interdisciplinary team managing these patients.
Styles APA, Harvard, Vancouver, ISO, etc.
19

Avdeev, S. N. « Idiopathic pulmonary fibrosis ». Russian Pulmonology 25, no 5 (1 janvier 2015) : 600–612. http://dx.doi.org/10.18093/0869-0189-2015-25-5-600-612.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
20

Man, Luo, et Peng Hong. « Idiopathic Pulmonary Fibrosis ». Chinese Medical Journal 130, no 17 (septembre 2017) : 2140–41. http://dx.doi.org/10.4103/0366-6999.213423.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Thompson, Austin B., John R. Spurzem et Stephen I. Rennard. « IDIOPATHIC PULMONARY FIBROSIS ». Immunology and Allergy Clinics of North America 12, no 2 (mai 1992) : 401–19. http://dx.doi.org/10.1016/s0889-8561(22)00116-3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
22

Selman, Mois??s, Victor J. Thannickal, Annie Pardo, David A. Zisman, Fernando J. Martinez et Joseph P. Lynch. « Idiopathic Pulmonary Fibrosis ». Drugs 64, no 4 (2004) : 405–30. http://dx.doi.org/10.2165/00003495-200464040-00005.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
23

Skvortsov, Vsevolod V., Arina N. Gorbach, Elena V. Belyakova, Ekaterina M. Skvortsova et Nikita D. Matveyev. « Idiopathic pulmonary fibrosis ». Meditsinskaya sestra 23, no 7 (2021) : 42–45. http://dx.doi.org/10.29296/25879979-2021-07-09.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
24

Skvortsov, Vsevolod Vladimirovich, Arina Nikolaevna Gorbach, Elena Vladimirovna Belyakova, Ekaterina Mikhailovna Skvortsova et Nikita Dmitrievich Matveyev. « Idiopathic pulmonary fibrosis ». Meditsinskaya sestra 24, no 2 (2022) : 16–19. http://dx.doi.org/10.29296/25879979-2022-02-04.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
25

Avdeev, S. N. « Idiopathic pulmonary fibrosis ». Consilium Medicum 19, no 3 (2017) : 17–23. http://dx.doi.org/10.26442/2075-1753_19.3.17-23.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
26

Gross, Thomas J., et Gary W. Hunninghake. « Idiopathic Pulmonary Fibrosis ». New England Journal of Medicine 345, no 7 (16 août 2001) : 517–25. http://dx.doi.org/10.1056/nejmra003200.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
27

Lederer, David J., et Fernando J. Martinez. « Idiopathic Pulmonary Fibrosis ». New England Journal of Medicine 378, no 19 (10 mai 2018) : 1811–23. http://dx.doi.org/10.1056/nejmra1705751.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
28

Lynch, Joseph P., Michael C. Fishbein, Rajeev Saggar, David A. Zisman et John A. Belperio. « Idiopathic pulmonary fibrosis ». Expert Review of Respiratory Medicine 1, no 3 (décembre 2007) : 377–89. http://dx.doi.org/10.1586/17476348.1.3.377.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
29

Flaherty, Kevin R., Adin-Cristian Andrei, Susan Murray, Chris Fraley, Thomas V. Colby, William D. Travis, Vibha Lama et al. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 174, no 7 (octobre 2006) : 803–9. http://dx.doi.org/10.1164/rccm.200604-488oc.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
30

Antoniou, Katerina M., David M. Hansell, Michael B. Rubens, Katharina Marten, Sujal R. Desai, Nikolaos M. Siafakas, Andrew G. Nicholson, Roland M. du Bois et Athol U. Wells. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 177, no 2 (15 janvier 2008) : 190–94. http://dx.doi.org/10.1164/rccm.200612-1759oc.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
31

Thannickal, Victor J., et James E. Loyd. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 178, no 7 (octobre 2008) : 663–65. http://dx.doi.org/10.1164/rccm.200807-1127ed.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
32

Zisman, David A., et Steven M. Kawut. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 178, no 12 (15 décembre 2008) : 1192–93. http://dx.doi.org/10.1164/rccm.200808-1339ed.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
33

Tierney, Lawrence. « Idiopathic Pulmonary Fibrosis ». Seminars in Respiratory and Critical Care Medicine 12, no 03 (juillet 1991) : 229–37. http://dx.doi.org/10.1055/s-2007-1006242.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
34

Dempsey, O. J., et D. Miller. « Idiopathic pulmonary fibrosis ». BMJ 347, no 07 4 (7 novembre 2013) : f6579. http://dx.doi.org/10.1136/bmj.f6579.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
35

Salisbury, Margaret L., Meng Xia, Yueren Zhou, Susan Murray, Nabihah Tayob, Kevin K. Brown, Athol U. Wells, Shelley L. Schmidt, Fernando J. Martinez et Kevin R. Flaherty. « Idiopathic Pulmonary Fibrosis ». Chest 149, no 2 (février 2016) : 491–98. http://dx.doi.org/10.1378/chest.15-0530.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
36

Swigris, Jeffrey J., Ware G. Kuschner, Jennifer L. Kelsey et Michael K. Gould. « Idiopathic Pulmonary Fibrosis ». Chest 127, no 1 (janvier 2005) : 275–83. http://dx.doi.org/10.1378/chest.18.4.330.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
37

Du Bois, R. M. « Idiopathic Pulmonary Fibrosis ». Annual Review of Medicine 44, no 1 (février 1993) : 441–50. http://dx.doi.org/10.1146/annurev.me.44.020193.002301.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
38

DOUGLAS, WILLIAM W, JAY H RYU et DARRELL R SCHROEDER. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 161, no 4 (avril 2000) : 1172–78. http://dx.doi.org/10.1164/ajrccm.161.4.9907002.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
39

Katzenstein, Anna-Luise A., et Jeffrey L. Myers. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 164, no 2 (15 juillet 2001) : 185–86. http://dx.doi.org/10.1164/ajrccm.164.2.2105010a.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
40

KING, TALMADGE E, MARVIN I SCHWARZ, KEVIN BROWN, JANET A TOOZE, THOMAS V COLBY, JAMES A WALDRON, ANDREW FLINT, WILLIAM THURLBECK et REUBEN M CHERNIACK. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 164, no 6 (15 septembre 2001) : 1025–32. http://dx.doi.org/10.1164/ajrccm.164.6.2001056.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
41

Thannickal, Victor. « Idiopathic Pulmonary Fibrosis ». Seminars in Respiratory and Critical Care Medicine 27, no 6 (décembre 2006) : 567–68. http://dx.doi.org/10.1055/s-2006-957327.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
42

du Bois, Roland M., Steven D. Nathan, Luca Richeldi, Marvin I. Schwarz et Paul W. Noble. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 186, no 8 (15 octobre 2012) : 712–15. http://dx.doi.org/10.1164/rccm.201206-1010pp.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
43

Kamp, David W. « Idiopathic Pulmonary Fibrosis ». Chest 124, no 4 (octobre 2003) : 1187–90. http://dx.doi.org/10.1378/chest.124.4.1187.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
44

Swigris, Jeffrey J. « Idiopathic Pulmonary Fibrosis* ». CHEST Journal 127, no 1 (1 janvier 2005) : 275. http://dx.doi.org/10.1378/chest.127.1.275.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
45

Ahmed, Ala'Eldin H. « Idiopathic Pulmonary Fibrosis ». Chest 127, no 2 (février 2005) : 694. http://dx.doi.org/10.1378/chest.127.2.694.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
46

Horowitz, Jeffrey C., et Victor J. Thannickal. « Idiopathic Pulmonary Fibrosis ». Treatments in Respiratory Medicine 5, no 5 (2006) : 325–42. http://dx.doi.org/10.2165/00151829-200605050-00004.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
47

Lindell, Kathleen Oare, et Susan S. Jacobs. « Idiopathic Pulmonary Fibrosis ». AJN, American Journal of Nursing 103, no 4 (avril 2003) : 32–42. http://dx.doi.org/10.1097/00000446-200304000-00016.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
48

McDonald, John A. « Idiopathic Pulmonary Fibrosis ». Chest 99, no 3 (mars 1991) : 87S—93S. http://dx.doi.org/10.1378/chest.99.3_supplement.87s.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
49

POCHIS, WILLIAM T., ARTHUR Z. KRASNOW, B. DAVID COLLIER, MARK W. MEWISSEN, URIAS A. ALMAGRO, ROBERT S. HELLMAN et ALI T. ISITMAN. « Idiopathic Pulmonary Fibrosis ». Clinical Nuclear Medicine 15, no 5 (mai 1990) : 321–23. http://dx.doi.org/10.1097/00003072-199005000-00009.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
50

Wells, Athol U., Sujal R. Desai, Michael B. Rubens, Nicole S. L. Goh, Derek Cramer, Andrew G. Nicholson, Thomas V. Colby, Roland M. du Bois et David M. Hansell. « Idiopathic Pulmonary Fibrosis ». American Journal of Respiratory and Critical Care Medicine 167, no 7 (avril 2003) : 962–69. http://dx.doi.org/10.1164/rccm.2111053.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Idiopathic pulmonary fibrosi » pour d’autres types de sources :
Thèses Livres
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie